Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...

Today we have a guest blog post from Dr John Rex, VP Clinical Infection at AstraZeneca. John’s post is on the heels of today’s news about the Innovative Medicines Initiative’s ...

AstraZeneca AZN-0.32%decrease; red down pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

Antibiotics given during infancy produce changes in the microbiome that may raise the risk for childhood asthma by 30%, suggested two posters presented on February 28 at the American Academy of ...

AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...

[HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual ...